The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a ‘danger to health’.

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...

Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...

View the latest Valneva SE ADR (VALN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...